-
Zhongchao and Johnson & Johnson Renew Partnership for Digital Health Services
•
Introduction Zhongchao Inc. (NASDAQ: ZCMD), a Shanghai-based online health education provider, has announced a renewed agreement with US major Johnson & Johnson (J&J, NYSE: JNJ). This partnership, initially established in 2017 and renewed in 2020, is expected to further enhance cooperation in the innovative healthcare field. Specifically, Zhongchao will provide…
-
CStone’s Sugemalimab Accepted for EU Marketing Authorization by EMA
•
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the European Medicine Agency (EMA) has accepted a marketing authorization application (MAA) submitted by its US-based partner EQRx for sugemalimab, a programmed death-1 (PD-1) inhibitor. The application is for the use of sugemalimab in combination with chemotherapy as a first-line treatment for…
-
Danatlas Raises Pre-Series A Funding for Synthetic Lethality Drug Development
•
Beijing-headquartered Danatlas, a first-in-class drug developer specializing in the synthetic lethality field, has reportedly raised “tens of millions” of renminbi in a Pre-Series A financing round. The round was led by Sequoia Capital China and Sherpa Healthcare Partners, with proceeds intended to accelerate the company’s drug research and development (R&D),…
-
CDE Signals Priority Review for Sanofi’s Dupixent and Other Drugs
•
The Center for Drug Evaluation (CDE) website indicates that France major Sanofi’s (NASDAQ: SNY) Dupixent (dupilumab), Sino-US biotech LianBio’s mavacamten, and Anhui Wotai Bio-pharmaceutical Co., Ltd’s sodium benzoate and sodium phenylacetate are on course to obtain priority review statuses. This development highlights the potential of these drugs to address significant…
-
InnoCare and Keymed Announce First Dosing of ICP-B05 Clinical Study
•
China-based firms InnoCare Pharma (HKG: 9969, SHA: 688428) and Keymed Biosciences (HKG: 2162) have jointly announced the first subject dosing of a clinical study for ICP-B05 (CM369), an anti-CC chemokine receptor 8 (CCR8) monoclonal antibody (mAb) developed by their joint venture, Tiannuojiancheng Pharma. This marks a significant milestone in the…
-
Luye Pharma’s Paliperidone Palmitate Approved for European Clinical Trials
•
China-based Luye Pharma Group (HKG: 2186) has announced receiving clinical trial approval in Europe for its paliperidone palmitate extended-release injectable suspension (LY03010). This approval marks a significant step forward in the development of this second-generation antipsychotic drug, which is designed for the treatment of schizophrenia and schizoaffective disorders. Paliperidone Palmitate:…
-
Bio-Thera Solutions Partners with China Resource Medicine for Integrated Collaboration
•
China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced a strategic partnership with compatriot firm China Resource Medicine Commercial Holdings Ltd to form an in-depth collaboration both online and offline. The partnership aims to enhance the distribution and accessibility of novel drugs and biosimilars in the Chinese market. No financial details…
-
NMPA Approves STmed’s ECMO Product for Market
•
The National Medical Products Administration (NMPA) has approved STmed Technology’s extracorporeal cardiopulmonary support auxiliary equipment and centrifugal pump head for marketing. This approval marks a significant milestone in the development of domestic medical technology, as the product is the third China-made extracorporeal membrane oxygenation (ECMO) product in the country. Product…
